640 related articles for article (PubMed ID: 10103174)
1. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).
Petersen PJ; Jacobus NV; Weiss WJ; Sum PE; Testa RT
Antimicrob Agents Chemother; 1999 Apr; 43(4):738-44. PubMed ID: 10103174
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines.
Testa RT; Petersen PJ; Jacobus NV; Sum PE; Lee VJ; Tally FP
Antimicrob Agents Chemother; 1993 Nov; 37(11):2270-7. PubMed ID: 8285606
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.
Projan SJ
Pharmacotherapy; 2000 Sep; 20(9 Pt 2):219S-223S; discussion 224S-228S. PubMed ID: 11001329
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
Tuckman M; Petersen PJ; Howe AY; Orlowski M; Mullen S; Chan K; Bradford PA; Jones CH
Antimicrob Agents Chemother; 2007 Sep; 51(9):3205-11. PubMed ID: 17620376
[TBL] [Abstract][Full Text] [Related]
5. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.
Biedenbach DJ; Beach ML; Jones RN
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):173-7. PubMed ID: 11576790
[TBL] [Abstract][Full Text] [Related]
6. Activities of the glycylcyclines N,N-dimethylglycylamido-minocycline and N,N-dimethylglycylamido-6-demethyl-6-deoxytetracycline against Nocardia spp. and tetracycline-resistant isolates of rapidly growing mycobacteria.
Brown BA; Wallace RJ; Onyi G
Antimicrob Agents Chemother; 1996 Apr; 40(4):874-8. PubMed ID: 8849243
[TBL] [Abstract][Full Text] [Related]
7. N,N-dimethylglycyl-amido derivative of minocycline and 6-demethyl-6-desoxytetracycline, two new glycylcyclines highly effective against tetracycline-resistant gram-positive cocci.
Goldstein FW; Kitzis MD; Acar JF
Antimicrob Agents Chemother; 1994 Sep; 38(9):2218-20. PubMed ID: 7811053
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
Sum PE; Petersen P
Bioorg Med Chem Lett; 1999 May; 9(10):1459-62. PubMed ID: 10360756
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline.
Macone AB; Caruso BK; Leahy RG; Donatelli J; Weir S; Draper MP; Tanaka SK; Levy SB
Antimicrob Agents Chemother; 2014; 58(2):1127-35. PubMed ID: 24295985
[TBL] [Abstract][Full Text] [Related]
10. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to new glycylcyclines in comparison with those to older tetracyclines.
Kenny GE; Cartwright FD
Antimicrob Agents Chemother; 1994 Nov; 38(11):2628-32. PubMed ID: 7872759
[TBL] [Abstract][Full Text] [Related]
11. Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936).
Hirata T; Saito A; Nishino K; Tamura N; Yamaguchi A
Antimicrob Agents Chemother; 2004 Jun; 48(6):2179-84. PubMed ID: 15155219
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline.
Honeyman L; Ismail M; Nelson ML; Bhatia B; Bowser TE; Chen J; Mechiche R; Ohemeng K; Verma AK; Cannon EP; Macone A; Tanaka SK; Levy S
Antimicrob Agents Chemother; 2015 Nov; 59(11):7044-53. PubMed ID: 26349824
[TBL] [Abstract][Full Text] [Related]
13. Recent developments in tetracycline antibiotics.
Sum PE; Sum FW; Projan SJ
Curr Pharm Des; 1998 Apr; 4(2):119-32. PubMed ID: 10197036
[TBL] [Abstract][Full Text] [Related]
14. Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris.
Zhanel G; Critchley I; Lin LY; Alvandi N
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397052
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of two glycylcyclines against gram-positive bacteria.
Eliopoulos GM; Wennersten CB; Cole G; Moellering RC
Antimicrob Agents Chemother; 1994 Mar; 38(3):534-41. PubMed ID: 8203851
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
Fritsche TR; Kirby JT; Jones RN
Diagn Microbiol Infect Dis; 2004 Jul; 49(3):201-9. PubMed ID: 15246511
[TBL] [Abstract][Full Text] [Related]
17. The glycylcyclines: a comparative review with the tetracyclines.
Zhanel GG; Homenuik K; Nichol K; Noreddin A; Vercaigne L; Embil J; Gin A; Karlowsky JA; Hoban DJ
Drugs; 2004; 64(1):63-88. PubMed ID: 14723559
[TBL] [Abstract][Full Text] [Related]
18. Tigecyclin--the first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline.
Felmingham D
J Chemother; 2005 Aug; 17 Suppl 1():5-11. PubMed ID: 16285353
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the in vitro activity of tigecycline against multiresistant Gram-positive cocci containing tetracycline resistance determinants.
Borbone S; Lupo A; Mezzatesta ML; Campanile F; Santagati M; Stefani S
Int J Antimicrob Agents; 2008 Mar; 31(3):209-15. PubMed ID: 17646087
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections.
Jones CH; Tuckman M; Howe AY; Orlowski M; Mullen S; Chan K; Bradford PA
Antimicrob Agents Chemother; 2006 Feb; 50(2):505-10. PubMed ID: 16436703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
